Fig. 1

A Measurable disease positivity from cerebrospinal fluid (CSF) samples collected at diagnosis or initial staging. B Exemplary case (GCT003) depicting tumor-concordant copy-number alterations inferred from low-pass whole-genome sequencing (LP-WGS) of cell-free DNA (cfDNA) extracted from CSF at diagnosis. C cfDNA concentrations in CSF samples collected at diagnosis, during therapy and after therapy, demonstrating a decreasing trend with therapy in our cohort